Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of fluorofenidone capsules at different doses for chronic hepatitis B-related liver fibrosis on tenofovir alafenamide background therapy
CTR20211557Phase 2Active
- Sponsor
- Haikou Pharmaceutical Factory Co., Ltd.
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluorofenidone, tenofovir alafenamide in hepatic fibrosis, Chronic Hepatitis B (CHB), sponsored by Haikou Pharmaceutical Factory Co., Ltd.. Started Dec 2021; status: active.
02
Drugs
fluorofenidonetenofovir alafenamide
03
Conditions
hepatic fibrosisChronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20211557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211557.